These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17109866)

  • 1. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients.
    Franceschini G; Calabresi L; Colombo C; Favari E; Bernini F; Sirtori CR
    Atherosclerosis; 2007 Dec; 195(2):385-91. PubMed ID: 17109866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
    Undas A; Celinska-Löwenhoff M; Domagala TB; Iwaniec T; Dropinski J; Löwenhoff T; Szczeklik A
    Thromb Haemost; 2005 Jul; 94(1):193-9. PubMed ID: 16113803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
    Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
    J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M; Steinmetz A; Retterstøl K; Császár A
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
    Foucher C; Aubonnet P; Reichert P; Berli M; Schaeffer A; Calvo Vargas CG; Lochocka A; Belenky D; Koch HF;
    Cardiovasc Ther; 2015 Dec; 33(6):329-37. PubMed ID: 26227087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.
    Niesor EJ; Schwartz GG; Perez A; Stauffer A; Durrwell A; Bucklar-Suchankova G; Benghozi R; Abt M; Kallend D
    Cardiovasc Drugs Ther; 2015 Feb; 29(1):7-14. PubMed ID: 25749868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M; Retterstøl K; Steinmetz A; Császár A
    Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits.
    Fournier N; Tuloup-Minguez V; Pourci ML; Thérond P; Jullian JC; Wien F; Leroy M; Dallongeville J; Paul JL; Leroy A
    Biochimie; 2013 Jun; 95(6):1278-87. PubMed ID: 23410672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
    Hamilton SJ; Chew GT; Davis TM; Watts GF
    Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
    Hossain MA; Tsujita M; Gonzalez FJ; Yokoyama S
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):258-66. PubMed ID: 18356690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein.
    Lie J; Lankhuizen IM; Gross B; van Gent T; van Haperen R; Scheek L; Staels B; de Crom R; van Tol A
    Biochim Biophys Acta; 2005 Dec; 1738(1-3):48-53. PubMed ID: 16298159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.